文献速递技术与安全神经泌尿生殖PETCTMR

将诊疗一体化整合到患者诊疗路径:AJR专家小组叙述性综述

Integrating Theranostics Into Patient Care Pathways: AJR Expert Panel Narrative Review.
PubMed 文献 · AJR Am J Roentgenol · 2022-11-02

本文综述了实体恶性肿瘤诊疗一体化(theranostics)的临床应用经验,重点讨论β发射体治疗(包括神经内分泌肿瘤的生长抑素类似物放射性配体、前列腺癌的PSMA靶向治疗、神经嵴起源肿瘤的131I-MIBG治疗)如何整合到患者诊疗路径中。文章还讨论了治疗相关毒性及不良事件后终止治疗的指征,并强调多学科团队在识别可能应答患者、确定最佳治疗时机和全程管理中的关键作用。

要点

  • 诊疗一体化将诊断生物标志物与治疗药物配对,靶向肿瘤细胞或其微环境共同靶点。
  • β发射体治疗已用于神经内分泌肿瘤、前列腺癌和神经嵴起源肿瘤。
  • 多学科团队协作是放射性诊疗一体化项目成功的关键。

核心结论

  • 诊疗一体化偶联诊断成像与局部高能粒子辐射,靶向表达共同靶点的组织,已进入美国临床实践并有望成为癌症治疗主力。

研究设计与样本

  • 本文为AJR专家小组叙述性综述,回顾实体恶性肿瘤诊疗一体化的经验并讨论实际整合。

临床应用与阅片要点

  • 多学科团队协作识别最可能应答的患者、确定最佳治疗时机并全程管理患者。
  • 需关注诊疗一体化给药相关毒性及不良事件后终止治疗的指征。
  • 将β发射体治疗(生长抑素类似物放射性配体、PSMA靶向治疗、131I-MIBG治疗)整合到诊疗路径中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Theranostics describes the coupling of a diagnostic biomarker and a therapeutic agent (i.e., a theranostic pair) that have a common target in tumor cells or their microenvironment. The term is increasingly associated with in vivo nuclear medicine oncologic applications that couple diagnostic imaging by means of gamma radiation with concomitant localized high-energy particulate radiation to a tissue expressing the common target. Several theranostic pairs have been translated into clinical practice in the United States and are poised to become a mainstay of cancer treatment. The purposes of this article are to review experience with theranostics for solid-organ malignancies and to address the practical integration into care pathways of β-emitting therapies that include somatostatin analogue radioligands for neuroendocrine tumors, PSMA-directed therapy for prostate cancer, and 131I-MIBG therapy for tumors of neural crest origin. Toxicities related to theranostics administration and indications for cessation of therapy in patients who experience adverse events are also discussed. A multidisciplinary team-based approach for identifying patients most likely to respond to these agents, determining the optimal time for therapy delivery, and managing patient care throughout the therapeutic course is critical to the success of a radiotheranostic program.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. O'Shea, Iravani, Saboury, et al. Integrating Theranostics Into Patient Care Pathways: AJR Expert Panel Narrative Review. AJR Am J Roentgenol. 2022. PMID: 36321986. doi:10.2214/AJR.22.28237

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。